AI-generated summary
The authors report a double-blind randomized trial of transcranial laser therapy versus sham in 660 patients with acute ischemic stroke. The primary efficacy outcome did not reach statistical significance (36.3% versus 30.9% favorable outcome, P=0.094), and safety outcomes, including mortality and serious adverse events, did not differ between groups.
- Participants
- 660
- Who or what was studied
- Patients with acute ischemic stroke treated within 24 hours of onset, excluding those receiving tissue plasminogen activator or with hemorrhagic infarct
- Limits stated in the abstract
- The primary efficacy end point did not reach significance, and the favorable-outcome finding in patients with baseline NIHSS below 16 came from a post hoc analysis.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on ahajournals.org.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Stroke, Laser, Sham, Statistical significance, Adverse event, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.